Simvastatin in aneurysmal subarachnoid haemorrhage: a multicentre, randomised controlled, clinical phase III study

Cambridge University Hospitals NHS Foundation Trust (UK)0 个研究点目标入组 800 人开始时间: 2006年4月4日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Patients aged 18-65 years
•2. If the admitting neurosurgeon has a high index of suspicion of a spontaneous aneurysmal subarachnoid haemorrhage (good clinical history with convincing computerised tomography [CT] findings)
•3. Any clinical grade accepted provided there is a reasonable prospect of survival
•4. Delay to randomisation and initiation of trial medication, from the time of the presenting bleed, does not exceed 96 hours
•5. Independent prior to the SAH

•1. Unsalvageable patients: fixed and dilated pupils after resuscitation, and/or a devastating scan, which precludes definitive therapy
•2. Already taking statin therapy
•3. Those taking warfarin-type drugs
•4. Pregnancy
•5. Known renal or hepatic impairment
•6. Suspected or known additional disease process, which threatens life expectancy (e.g. malignancy)
•7. Known or strong suspicion of drug abuse, alcoholism, or those who are unlikely to be amenable to six-month follow up

发起方